Get access

A bird's-eye view of cell therapy and tissue engineering for cardiac regeneration

Authors

  • Carolina Soler-Botija,

    1. Heart Failure and Cardiac Regeneration (ICREC) Research Program, Health Research Institute Germans Trias i Pujol (IGTP), Cardiology Service, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
    Search for more papers by this author
  • Juli R. Bagó,

    1. Networking Biomedical Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain.
    2. Cardiovascular Research Center (CSIC-ICCC), Barcelona, Spain.
    Search for more papers by this author
  • Antoni Bayes-Genis

    1. Heart Failure and Cardiac Regeneration (ICREC) Research Program, Health Research Institute Germans Trias i Pujol (IGTP), Cardiology Service, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
    2. Networking Biomedical Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain.
    3. Department of Medicine, Autonomous University Barcelona, Barcelona, Spain
    Search for more papers by this author

Errata

This article is corrected by:

  1. Errata: Corrigendum for Ann. N.Y. Acad. Sci. 2012. 1254: 57–65 Volume 1270, 121, Article first published online: 10 October 2012

Address for correspondence: Antoni Bayes-Genis, M.D., Ph.D., F.E.S.C., I.C.R.E.C. (Heart Failure and Cardiac Regeneration) Research Group, Cardiology Service, University Hospital Germans Trias i Pujol, Crta. Canyet, s/n, 08916 Badalona, Barcelona, Spain; and Department of Medicine, Autonomous University Barcelona (UAB), Barcelona, Spain. abayesgenis@gmail.com

Abstract

Complete recovery of ischemic cardiac muscle after myocardial infarction is still an unresolved concern. In recent years, intensive research efforts have focused on mimicking the physical and biological properties of myocardium for cardiac repair. Here we show how heart regeneration approaches have evolved from cell therapy to refined tissue engineering. Despite progressive improvements, the best cell type and delivery strategy are not well established. Our group has identified a new population of cardiac adipose tissue–derived progenitor cells with inherent cardiac and angiogenic potential that is a promising candidate for cell therapy to restore ischemic myocardium. We also describe results from three strategies for cell delivery into a murine model of myocardial infarction: intramyocardial injection, implantation of a fibrin patch loaded with cells, and an engineered bioimplant (a combination of chemically designed scaffold, peptide hydrogel, and cells); dual-labeling noninvasive bioluminescence imaging enables in vivo monitoring of cardiac-specific markers and cell survival.

Ancillary